To avoid being charged the recurring subscription fee, simply cancel before the free-trial period ends - it’s just $4.99/mo afterward. *To avoid being charged the recurring subscription fee ...

The standalone McAfee AntiVirus now covers just one PC for $49.99 per year, sold only through third-party sites and with no volume discount. McAfee Total Protection, reviewed here, starts at $89. ...

Krishi Chowdhary has half a decade of experience writing buying guides and product reviews for numerous leading technology websites. He spent two years writing for… The best antivirus software will ...

Instead, major antivirus providers including Avast and McAfee have developed mobile security apps for iOS. These apps don’t function as traditional antiviruses, instead working more like virtual ...

Whether you’re concerned about your data privacy or are simply looking for a replacement antivirus solution, there are a range of strong alternative options available. In this guide, I’ll present you ...

Worried about security and privacy when you’re using your smartphone? Explore our guide to the best VPN for Android for our ...

There's an easy way to make sure the one you pick is right for you, though – and that's by using one of the best VPN free trials ... security suite with antivirus-like features at no extra ...

You don't have to pay extra, though. We’ve tested and ranked the best free antivirus apps. When the IBM PC was new, I served as the president of the San Francisco PC User Group for three years.

"Per the approved protocol, approximately 700 high-risk adults, starting with health care providers, will be dosed at six clinical trial sites in Rwanda," the institute said in a statement.

Image credit: MiniStocker / Shutterstock. Oncolytics Biotech is seeking accelerated approval for its lead cancer therapy, pelareorep, with plans to start a registrational Phase II breast cancer trial.

Avira’s paid products are regularly assessed by the top antivirus labs, giving a useful general idea of how Avira compares to the competition. Avira’s overall results are a little disappointing right ...